Antibody Fragments Market to Reach USD 16.61 Billion by 2035, Growing at a CAGR of 6.2%

​The global antibody fragments market is experiencing significant growth, driven by advancements in biotechnology, increasing prevalence of chronic diseases, and the rising demand for targeted therapies. Antibody fragments, which are portions of full-length antibodies, retain the antigen-binding sites and offer unique advantages over traditional monoclonal antibodies, such as improved tissue penetration and reduced immunogenicity. This comprehensive analysis delves into the market dynamics, segmentation, regional insights, and future outlook of the antibody fragments market.​

The global antibody fragments market is expected to reach USD 16,607 million by 2035, up from USD 8,563 million in 2024. During the forecast period (2025 to 2035), the industry is projected to expand at a CAGR of 6.2%. The antibody fragments market is expected to expand with expanded usage in targeted medicines, additional application in biologics, and emergent recombinant DNA technologies.This growth is primarily attributed to the increasing adoption of antibody fragments in therapeutic applications, particularly in oncology and immunology.​

For More Insights into the Market, Request a Sample of this Report:https://www.factmr.com/connectus/sample?flag=S&rep_id=7995

Key Drivers of Market Growth

Advancements in Biotechnology and Genetic Engineering

The introduction of recombinant DNA technology has revolutionized the development of antibody fragments. Techniques such as phage display and transgenic mice have enabled the production of fragments with enhanced specificity and affinity, facilitating their use in targeted therapies. These technological advancements have expanded the potential applications of antibody fragments in various therapeutic areas

Rising Prevalence of Chronic Diseases

The increasing incidence of chronic diseases, including cancer and autoimmune disorders, has led to a heightened demand for effective and targeted treatment options. Antibody fragments offer advantages such as improved tumor penetration and reduced side effects, making them suitable candidates for addressing these medical challenges.​

Growing Demand for Targeted Therapies

There is a significant shift towards personalized medicine, emphasizing treatments tailored to individual patient profiles. Antibody fragments, known for their ability to be customized to interact with specific antigens, are emerging as prime candidates for targeted therapies, especially in oncology and immunology. ​

Market Segmentation

The antibody fragments market can be segmented based on specificity, type, therapy, application, and region.

By Specificity

Monoclonal Antibodies: Dominated the market with a revenue share of over 95.0% in 2023. ​

Polyclonal Antibodies: Hold a smaller market share but are utilized in various therapeutic and diagnostic applications.​
By Type

Fragment Antigen-Binding (Fab): Captured the largest revenue share of over 85.0% in 2023.
Single-Chain Variable Fragments (scFv): Anticipated to register the fastest growth rate over the forecast period due to advantages such as low molecular weight and high tumor penetration.

Single-Domain Antibodies (sdAb): Gaining attention for their stability and high binding affinity, making them suitable for oncology and immunotherapy applications.

By Therapy

Monoclonal Antibodies: Led the market and held a revenue share of over 95.0% in 2023. ​

Polyclonal Antibodies (PAB): Utilized in specific therapeutic contexts, though with a smaller market presence.​

Pipeline Therapies: Emerging treatments under development that are expected to contribute to market growth in the coming years.​

By Application

Immunodeficiency: Held the largest revenue share of over 85.0% in 2023, driven by the increasing prevalence of immunodeficiency diseases. ​

Cancer: Expected to witness the fastest growth during the forecast period due to the high incidence of cancer globally and the effectiveness of antibody fragments in targeted cancer therapies.

Others: Including chronic diseases such as age-related macular degeneration (AMD) and infectious diseases like HIV/AIDS and influenza.
Regional Insights

North America

Dominated the market in 2023 with a revenue share of over 53.0%, attributed to the expansion of pharmaceutical industries and the increasing prevalence of immunodeficiency diseases and cancer. ​

Europe

Holds a significant market share, supported by strong research initiatives and favorable government policies promoting biotechnological advancements. ​

Asia Pacific

Anticipated to witness significant growth over the forecast period, driven by developing medical tourism markets and a growing focus on biologics manufacturing in countries like India and China. ​

Latin America and Middle East & Africa

These regions are expected to experience moderate growth, influenced by increasing healthcare investments and a rising burden of chronic diseases.​

Competitive Landscape

The antibody fragments market is highly competitive, with several global and regional players striving for market share. Key companies include:​

Pfizer Inc.
Ablynx
Novartis AG
Genentech, Inc.
AbbVie Inc.
Bristol-Myers Squibb Company
Johnson & Johnson Private Limited
Eli Lilly and Co.

Get Customization on this Report for Specific Research Solutions :https://www.factmr.com/connectus/sample?flag=S&rep_id=7995

These companies are actively engaged in research and development activities, product launches, and strategic collaborations to strengthen their market positions. ​

Recent Developments

June 2022: The FDA approved Beovu (brolucizumab-dbl), an antibody fragment, for the treatment of diabetic macular edema (DME). ​
Explore More Related Studies Published by Fact.MR Research:

Surgical Dental Loupe and Camera Market

https://www.factmr.com/report/surgical-dental-loupe-and-camera-market

Temporary Cardiac Pacing Wire and Lead Market

https://www.factmr.com/report/temporary-cardiac-pacing-wire-and-lead-market

Private Healthcare Industry Analysis in United Kingdom

https://www.factmr.com/report/private-healthcare-industry-analysis-in-united-kingdom

Smart Inhaler Market

https://www.factmr.com/report/smart-inhaler-market

Physical Therapy Services Market

https://www.factmr.com/report/physical-therapy-services-market

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com

About Fact.MR:

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.